Home › Myelofibrosis › Virginia
Myelofibrosis clinical trials in Virginia
7 studies for Myelofibrosis are looking for participants at sites in Virginia.
Cities in Virginia
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07357727A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06661915A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
- Site US23, Richmond
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07849231A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Virginia Cancer Center, Charlottesville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Virginia, Charlottesville
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Virginia Cancer Institute, Richmond
- VCU Medical Center, Richmond
- Virginia Oncology Associates - Virginia Beach, Virginia Beach
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.